Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

NCT07053215 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DEVICE: Argon-Helium Cryoablation
DRUG: Camrelizumab
DRUG: Platinum-based doublet chemotherapy

Sponsor

The First Hospital of Hebei Medical University